TRex Bio, Inc. (NASDAQ:TRXB – Get Free Report) major shareholder Alexandria Venture Investments acquired 178,571 shares of the firm’s stock in a transaction dated Tuesday, October 13th. The stock was purchased at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the transaction, the insider owned 1,346,501 shares in the company, valued at approximately $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
TRex Bio Trading Down 1.1%
Shares of TRXB opened at $14.01 on Friday. TRex Bio, Inc. has a fifty-two week low of $13.21 and a fifty-two week high of $15.50.
About TRex Bio
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.
Featured Articles
- Five stocks we like better than TRex Bio
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.
